• 1.大連友誼醫(yī)院外二科（大連116001）;;
  • 2.安徽醫(yī)科大學(xué)第一附屬醫(yī)院普外科（合肥230022）;

目的探討生長抑素對人胃癌細胞的抑制作用及其作用機理。方法以生長抑素類似物奧曲肽作用于人胃癌細胞株SGC7901細胞，以人成纖維細胞株HF作為正常細胞對照，以5FU作為陽性藥物對照，通過MTT實驗、熒光顯微鏡觀察及流式細胞術(shù)分析，得出結(jié)論。結(jié)果一定濃度范圍內(nèi)的奧曲肽對SGC7901細胞產(chǎn)生抑制作用，其抑制作用具有量效關(guān)系和飽和性。奧曲肽對SGC7901細胞的抑制程度接近于5FU對他的抑制，而對HF細胞無影響。奧曲肽可誘導(dǎo)SGC7901細胞凋亡。結(jié)論奧曲肽在體外對SGC7901細胞具有抑制作用，誘導(dǎo)腫瘤細胞凋亡可能是其作用機理之一。

引用本文： 呂文才,耿小平,孟翔,凌譚,文翔. 奧曲肽對人胃癌細胞的凋亡誘導(dǎo)作用. 中國普外基礎(chǔ)與臨床雜志, 2004, 11(3): 238-241. doi: 復(fù)制

1. Goldberg RM, Moertel CG, Wieand HS, et al. A phase Ⅲ evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. North Central Cancer Treatment Group and the Mayo Clinic [Ｊ]. Cancer, 1995; 76(6)∶ 961.
2. Tomassetti P, Migliori M, Gullo L. Slowrelease lanreotide treatment in endocrine gastrointestinal tumors [Ｊ]. Am J Gastroenterol， 1998; 93(9)∶1468.
3. Eriksson B, Renstrup J, Imam H, et al. Highdose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects [Ｊ]. Ann Oncol， 1997; 8(10)∶1041.
4. Madeira I, Ruszniewski P. Digestive system carcinoid tumors: treatment [Ｊ]. Rev Med Interne， 1999; 20(5)∶421.
5. 鄭永唐，賁昆龍. 測定細胞存活和增殖的MTT方法的建立 [Ｊ]. 免疫學(xué)雜志， 1992； 8（4）∶266.
6. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours [Ｊ]. Gut， 1996; 38(3)∶430.
7. Degen L, Beglinger C. The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors [Ｊ]. Digestion， 1999; 60（Suppl 2）∶9.
8. 鄂征主編. 組織培養(yǎng)和分子細胞學(xué)技術(shù) [M]. 第1版. 北京： 北京出版社， 1995∶203～205.
9. Di Leo A, Bajetta E, Ferrari L, et al. A dosefinding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma [Ｊ]. Cancer, 1996; 78(1)∶35.
10. Janson ET, Stridsberg M, Gobl A, et al. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies [Ｊ]. Cancer Res, 1998; 58(11)∶2375.
11. Qin Y, Ertl T, Groot K, et al. Somatostatin analog RC160 inhibits growth of CFPAC1 human pancreatic cancer cells in vitro and intracellular production of cyclic adenosine monophosphate [Ｊ]. Int J Cancer, 1995; 60(5)∶694.
12. Reisine T. Somatostatin receptors [Ｊ]. Am J Physiol， 1995; 269(6 Pt 1)∶G813.
13. 吳蘇冬， 劉長利， 王慧川， 等. 參臼膠囊誘導(dǎo)肝癌SMMC7721細胞凋亡 [Ｊ]. 世界華人消化雜志， 2003； 11（7）∶908.
  1. 1. Goldberg RM, Moertel CG, Wieand HS, et al. A phase Ⅲ evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. North Central Cancer Treatment Group and the Mayo Clinic [Ｊ]. Cancer, 1995; 76(6)∶ 961.
  2. 2. Tomassetti P, Migliori M, Gullo L. Slowrelease lanreotide treatment in endocrine gastrointestinal tumors [Ｊ]. Am J Gastroenterol， 1998; 93(9)∶1468.
  3. 3. Eriksson B, Renstrup J, Imam H, et al. Highdose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects [Ｊ]. Ann Oncol， 1997; 8(10)∶1041.
  4. 4. Madeira I, Ruszniewski P. Digestive system carcinoid tumors: treatment [Ｊ]. Rev Med Interne， 1999; 20(5)∶421.
  5. 5. 鄭永唐，賁昆龍. 測定細胞存活和增殖的MTT方法的建立 [Ｊ]. 免疫學(xué)雜志， 1992； 8（4）∶266.
  6. 6. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours [Ｊ]. Gut， 1996; 38(3)∶430.
  7. 7. Degen L, Beglinger C. The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors [Ｊ]. Digestion， 1999; 60（Suppl 2）∶9.
  8. 8. 鄂征主編. 組織培養(yǎng)和分子細胞學(xué)技術(shù) [M]. 第1版. 北京： 北京出版社， 1995∶203～205.
  9. 9. Di Leo A, Bajetta E, Ferrari L, et al. A dosefinding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma [Ｊ]. Cancer, 1996; 78(1)∶35.
  10. 10. Janson ET, Stridsberg M, Gobl A, et al. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies [Ｊ]. Cancer Res, 1998; 58(11)∶2375.
  11. 11. Qin Y, Ertl T, Groot K, et al. Somatostatin analog RC160 inhibits growth of CFPAC1 human pancreatic cancer cells in vitro and intracellular production of cyclic adenosine monophosphate [Ｊ]. Int J Cancer, 1995; 60(5)∶694.
  12. 12. Reisine T. Somatostatin receptors [Ｊ]. Am J Physiol， 1995; 269(6 Pt 1)∶G813.
  13. 13. 吳蘇冬， 劉長利， 王慧川， 等. 參臼膠囊誘導(dǎo)肝癌SMMC7721細胞凋亡 [Ｊ]. 世界華人消化雜志， 2003； 11（7）∶908.